Updates on Prevention of Hemorrhagic and Lacunar Strokes

키워드

참고문헌 (101)

1. Adams HP Jr, "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment", Stroke, 24, pp.35~41 (1993)[DOI]
2. Pantoni L, "Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges", Lancet Neurol, 9, pp.689~701 (2010)[DOI]
3. Qureshi AI, "Spontaneous intracerebral hemorrhage", N Engl J Med, 344, pp.1450~1460 (2001)[DOI]
4. Gurol ME, "Management of intracerebral hemorrhage", Curr Atheroscler Rep, 10, pp.324~331 (2008)[DOI]
5. 송태진, "Total Cerebral Small-Vessel Disease Score is Associated with Mortality during Follow-Up after Acute Ischemic Stroke", Journal of Clinical Neurology, 13(2), pp.187~195 (2017), 대한신경과학회[DOI]
6. Gurol ME, "Molecular neuroimaging in vascular cognitive impairment", Stroke, 47, pp.1146~1152 (2016)[DOI]
7. de Laat KF, "Gait in elderly with cerebral small vessel disease", Stroke, 41, pp.1652~1658 (2010)[DOI]
8. Fanning JP, "The epidemiology of silent brain infarction: a systematic review of population-based cohorts", BMC Med, 12, pp.119~ (2014)[DOI]
9. Wolma J, "Ethnicity a risk factor? The relation between ethnicity and large- and small-vessel disease in White people, Black people, and Asians within a hospitalbased population", Eur J Neurol, 16, pp.522~527 (2009)[DOI]
10. Vincent Mok, "Prevention and Management of Cerebral Small Vessel Disease", 대한뇌졸중영문학회지, 17(2), pp.111~122 (2015), 대한뇌졸중학회
11. Narayanaswamy Venketasubramanian, "Stroke Epidemiology in South, East, and South-East Asia: A Review", 대한뇌졸중영문학회지, 19(3), pp.286~294 (2017), 대한뇌졸중학회
12. 안상준, "Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update", 대한뇌졸중영문학회지, 19(1), pp.3~10 (2017), 대한뇌졸중학회
13. Jin C, "Prospective study of fasting blood glucose and intracerebral hemorrhagic risk", Stroke, 49, pp.27~33 (2018)[DOI]
14. Lauer A, "Statins in intracerebral hemorrhage", Curr Atheroscler Rep, 17, pp.46~ (2015)[DOI]
15. Breteler MM, "Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study", Neurology, 44, pp.1246~1252 (1994)[DOI]
16. Charidimou A, "MRI-visible perivascular spaces in cerebral amyloid angiopathy and hypertensive arteriopathy", Neurology, 88, pp.1157~1164 (2017)[DOI]
17. Pasi M, "Mixed-location cerebral hemorrhage", microbleeds: underlying microangiopathy and recurrence risk, 2018, pp.90, 119~126
18. Smith EE, "Mixed emotions: what to do with patients who have lobar and deep hemorrhages on MRI?", Neurology, 90, pp.55~56 (2018)[DOI]
19. Gurol ME, "Uncommon Causes of Stroke", pp.534~544 (2018), Cambridge University Press
20. Charidimou A, "Cortical superficial siderosis multifocality in cerebral amyloid angiopathy: a prospective study", Neurology, 89, pp.2128~2135 (2017)[DOI]
21. Knudsen KA, "Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria", Neurology, 56, pp.537~539 (2001)[DOI]
22. Linn J, "Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy", Neurology, 74, pp.1346~1350 (2010)[DOI]
23. Reijmer YD, "Ischemic brain injury in cerebral amyloid angiopathy", J Cereb Blood Flow Metab, 36, pp.40~54 (2016)[DOI]
24. Pasi M, "Distribution of lacunes in cerebral amyloid angiopathy and hypertensive small vessel disease", Neurology, 88, pp.2162~2168 (2017)[DOI]
25. Smith EE, "Lacunes: black holes in our understanding of cerebral amyloid angiopathy", Neurology, 88, pp.2158~2159 (2017)[DOI]
26. Verdura E, "Heterozygous HTRA1 mutations are associated with autosomal dominant cerebral small vessel disease", Brain, 138, pp.2347~2358 (2015)[DOI]
27. Di Donato I, "Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects", BMC Med, 15, pp.41~ (2017)[DOI]
28. Joutel A, "Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia", Nature, 383, pp.707~710 (1996)[DOI]
29. Chabriat H, "Cadasil", Lancet Neurol, 8, pp.643~653 (2009)[DOI]
30. Gunda B, "Effects of gender on the phenotype of CADASIL", Stroke, 43, pp.137~141 (2012)[DOI]
31. Chabriat H, "Predictors of clinical worsening in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: prospective cohort study", Stroke, 47, pp.4~11 (2016)[DOI]
32. Nozaki H, "Characteristic features and progression of abnormalities on MRI for CARASIL", Neurology, 85, pp.459~463 (2015)[DOI]
33. Mendioroz M, "A missense HTRA1 mutation expands CARASIL syndrome to the Caucasian population", Neurology, 75, pp.2033~2035 (2010)[DOI]
34. Nishimoto Y, "A novel mutation in the HTRA1 gene causes CARASIL without alopecia", Neurology, 76, pp.1353~1355 (2011)[DOI]
35. Plaisier E, "COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps", N Engl J Med, 357, pp.2687~2695 (2007)[DOI]
36. Verdura E, "Disruption of a miR-29 binding site leading to COL4A1 upregulation causes pontine autosomal dominant microangiopathy with leukoencephalopathy", Ann Neurol, 80, pp.741~753 (2016)[DOI]
37. Bugiani M, "Cathepsin A-related arteriopathy with strokes and leukoencephalopathy (CARASAL)", Neurology, 87, pp.1777~1786 (2016)[DOI]
38. Sellal F, "APP mutations in cerebral amyloid angiopathy with or without cortical calcifications: report of three families and a literature review", J Alzheimers Dis, 56, pp.37~46 (2017)[DOI]
39. Fotiadis P, "Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control study", Lancet Neurol, 15, pp.811~819 (2016)[DOI]
40. van Etten ES, "Recurrent hemorrhage risk and mortality in hereditary and sporadic cerebral amyloid angiopathy", Neurology, 87, pp.1482~1487 (2016)[DOI]
41. Martinez-Ramirez S, "Diagnostic value of lobar microbleeds in individuals without intracerebral hemorrhage", Alzheimers Dement, 11, pp.1480~1488 (2015)[DOI]
42. Wollenweber FA, "Cortical superficial siderosis in different types of cerebral small vessel disease", Stroke, 48, pp.1404~1407 (2017)[DOI]
43. Gurol ME, "Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy", Neurology, 66, pp.23~29 (2006)[DOI]
44. Gurol ME, "Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography", magnetic resonance imaging study, 2013, pp.73, 529~536
45. Charidimou A, "White matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathy", Neurology, 86, pp.505~511 (2016)[DOI]
46. Smith EE, "White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage", Neurology, 63, pp.1606~1612 (2004)[DOI]
47. Chen YW, "Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy", Neurology, 67, pp.83~87 (2006)[DOI]
48. Smith EE, "MRI markers of small vessel disease in lobar and deep hemispheric intracerebral hemorrhage", Stroke, 41, pp.1933~1938 (2010)[DOI]
49. Martinez-Ramirez S, "Topography of dilated perivascular spaces in subjects from a memory clinic cohort", Neurology, 80, pp.1551~1556 (2013)[DOI]
50. Verbeek MM, "Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy", Ann Neurol, 66, pp.245~249 (2009)[DOI]
51. Gurol ME, "Florbetapir-PET to diagnose cerebral amyloid angiopathy: a prospective study", Neurology, 87, pp.2043~2049 (2016)[DOI]
52. Reyes S, "Presymptomatic genetic testing in CADASIL", J Neurol, 259, pp.2131~2136 (2012)[DOI]
53. Auer DP, "Differential lesion patterns in CADASIL and sporadic subcortical arteriosclerotic encephalopathy: MR imaging study with statistical parametric group comparison", Radiology, 218, pp.443~451 (2001)[DOI]
54. van Etten ES, "Incidence of symptomatic hemorrhage in patients with lobar microbleeds", Stroke, 45, pp.2280~2285 (2014)[DOI]
55. Thon JM, "Intracranial hemorrhage risk in the era of antithrombotic therapies for ischemic stroke", Curr Treat Options Cardiovasc Med, 18, pp.29~ (2016)[DOI]
56. Puy L, "Cerebral microbleeds and the risk of incident ischemic stroke in CADASIL (Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy)", Stroke, 48, pp.2699~2703 (2017)[DOI]
57. Lee JS, "Cerebral microbleeds, hypertension, and intracerebral hemorrhage in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy", Front Neurol, 8, pp.203~ (2017)[DOI]
58. Rinnoci V, "Cerebral hemorrhages in CADASIL: report of four cases and a brief review", J Neurol Sci, 330, pp.45~51 (2013)[DOI]
59. Petty GW, "Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence", Stroke, 31, pp.1062~1068 (2000)[DOI]
60. SPS3 Investigators, "Effects of clopidogrel added to aspirin in patients with recent lacunar stroke", N Engl J Med, 367, pp.817~825 (2012)[DOI]
61. Hanger HC, "The risk of recurrent stroke after intracerebral haemorrhage", J Neurol Neurosurg Psychiatry, 78, pp.836~840 (2007)[DOI]
62. Haley KE, "Cerebral microbleeds and macrobleeds: should they influence our recommendations for antithrombotic therapies?", Curr Cardiol Rep, 15, pp.425~ (2013)[DOI]
63. Gurol ME, "Nonpharmacological management of atrial fibrillation in patients at high intracranial hemorrhage risk", Stroke, 49, pp.247~254 (2018)[DOI]
64. Kwok CS, "Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials", Stroke, 46, pp.1014~1023 (2015)[DOI]
65. Diener HC, "Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial", Lancet, 364, pp.331~337 (2004)[DOI]
66. Shinohara Y, "Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomized non-inferiority trial", Lancet Neurol, 9, pp.959~968 (2010)[DOI]
67. Culebras A, "Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study", Neurology, 62, pp.1073~1080 (2004)[DOI]
68. Uchiyama S, "Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2", Cerebrovasc Dis, 37, pp.296~303 (2014)[DOI]
69. Kim BJ, "Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial", Lancet Neurol, 17, pp.509~518 (2018)[DOI]
70. Kim JS, "Cilostazol research in Asia: can it be applied to European and American patients?", Int J Stroke, 10(Suppl 1), pp.1~9 (2015)
71. Mohr JP, "A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke", N Engl J Med, 345, pp.1444~1451 (2001)[DOI]
72. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group, "A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin", Ann Neurol, 42, pp.857~865 (1997)[DOI]
73. Bath PM, "Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions", Int J Stroke, 10, pp.469~478 (2015)[DOI]
74. Wilson D, "Intracerebral haemorrhage, atrial fibrillation, and anticoagulation", Lancet, 386, pp.1736~1737 (2015)
75. Wilson D, "Anticoagulation for atrial fibrillation in patients with cerebral microbleeds", Curr Atheroscler Rep, 17, pp.47~ (2015)[DOI]
76. Wang Z, "Cerebral microbleeds: is antithrombotic therapy safe to administer?", Stroke, 45, pp.2811~2817 (2014)[DOI]
77. Mehmet Akif Topcuoglu, "Updates on Prevention of Cardioembolic Strokes", 대한뇌졸중영문학회지, 20(2), pp.180~196 (2018), 대한뇌졸중학회
78. Biffi A, "Oral anticoagulation and functional outcome after intracerebral hemorrhage", Ann Neurol, 82, pp.755~765 (2017)[DOI]
79. Lammie GA, "Hypertensive cerebral small vessel disease and stroke", Brain Pathol, 12, pp.358~370 (2002)
80. Wardlaw JM, "Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging", Lancet Neurol, 12, pp.483~497 (2013)[DOI]
81. Arima H, "Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial", J Hypertens, 28, pp.395~400 (2010)[DOI]
82. Yusuf S, "Telmisartan to prevent recurrent stroke and cardiovascular events", N Engl J Med, 359, pp.1225~1237 (2008)[DOI]
83. SPS3 Study Group, "Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial", Lancet, 382, pp.507~515 (2013)[DOI]
84. Biffi A, "Association between blood pressure control and risk of recurrent intracerebral hemorrhage", JAMA, 314, pp.904~912 (2015)[DOI]
85. Li W, "Blood pressure trajectories and the risk of intracerebral hemorrhage and cerebral infarction: a prospective study", Hypertension, 70, pp.508~514 (2017)[DOI]
86. Huang Y, "Prehypertension and the risk of stroke: a meta-analysis", Neurology, 82, pp.1153~1161 (2014)[DOI]
87. Ling Y, "Predictors and clinical impact of incident lacunes in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy", Stroke, 48, pp.283~289 (2017)[DOI]
88. Pettersen JA, "CADASIL accelerated by acute hypotension: Arterial and venous contribution to leukoaraiosis", Neurology, 88, pp.1077~1080 (2017)[DOI]
89. Dekker JM, "Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study", Circulation, 112, pp.666~673 (2005)[DOI]
90. Najarian RM, "Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study", Arch Intern Med, 166, pp.106~111 (2006)[DOI]
91. Zhu S, "Recurrent vascular events in lacunar stroke patients with metabolic syndrome and", or diabetes, 2015, pp.85, 935~941
92. Boulanger M, "Association between diabetes mellitus and the occurrence and outcome of intracerebral hemorrhage", Neurology, 87, pp.870~878 (2016)[DOI]
93. Palacio S, "Lacunar strokes in patients with diabetes mellitus: risk factors, infarct location, and prognosis: the secondary prevention of small subcortical strokes study", Stroke, 45, pp.2689~2694 (2014)[DOI]
94. Stroke Prevetion by Aggressive Reduction in Cholestrol Levels (SPARCL) Investigators, "High-dose atorvastatin after stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators", J Cardiometab Syndr, 3, pp.68~69 (2008)[DOI]
95. Amarenco P, "High-dose atorvastatin after stroke or transient ischemic attack", N Engl J Med, 355, pp.549~559 (2006)[DOI]
96. Goldstein LB, "Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study", Neurology, 70(24), pp.2364~2370 (2008)[DOI]
97. Hassan A, "Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction", Brain, 127, pp.212~219 (2004)[DOI]
98. Maron BA, "The treatment of hyperhomocysteinemia", Annu Rev Med, 60, pp.39~54 (2009)[DOI]
99. Cavalieri M, "B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the VITAmins TO Prevent Stroke (VITATOPS) MRI-substudy", Stroke, 43, pp.3266~3270 (2012)[DOI]
100. Ikram MA, "Kidney function is related to cerebral small vessel disease", Stroke, 39, pp.55~61 (2008)[DOI]
101. Greenberg SM, "A phase 2 study of tramiprosate for cerebral amyloid angiopathy", Alzheimer Dis Assoc Disord, 20, pp.269~274 (2006)[DOI]

관련 논문AI추천